Hospital
Hospital Development of West Phoenix INC
Hospital Development of West Phoenix INC was paid $16.72M by Medicaid between Jan 2018 and Dec 2024, across 122 billing codes. Its largest line is 99284, emergency room visit (serious) — 28% of everything it billed.
33Billing provider infoHOSPITAL DEVELOPMENT OF WEST PHOENIX INC
BUCKEYE, AZ 85326
BUCKEYE, AZ 85326
33aNPI1528512407assigned 08/09/2016
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.72M
24GClaims319,828
24DCodes billed122
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#34 of 78
Median peer was paid$12.21M
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 52,160 | $2.45M | |
| 2019 | 26,029 | $1.29M | |
| 2020 | 20,866 | $943K | |
| 2021 | 31,748 | $1.47M | |
| 2022 | 70,990 | $3.46M | |
| 2023 | 66,015 | $3.82M | |
| 2024incomplete | 52,020 | $3.30M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 28% | 20,181 | 18,980 | $4.64M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 26,200 | 24,841 | $4.31M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 12,035 | 11,198 | $3.15M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 15% | 3,881 | 3,687 | $2.44M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.9% | 1,488 | 1,410 | $649K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.3% | 2,308 | 2,225 | $560K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.5% | 6,008 | 5,748 | $413K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 349 | 339 | $177K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 546 | 524 | $167K |
| 93975 | <1% | 261 | 251 | $35K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 633 | 596 | $31K |
| 12001 | <1% | 341 | 336 | $30K |
110 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,233 | $30K |
| 73562 | <1% | 292 | $28K | |
| 93971 | <1% | 175 | $23K | |
| 72131 | <1% | 31 | $12K | |
| 73630 | <1% | 1,019 | $5K | |
| 73130 | <1% | 773 | $4K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 106 | $3K |
| 73110 | <1% | 410 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,419 | $2K |
| 93976 | <1% | 507 | $2K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 10,443 | $2K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,861 | $848.14 |
| 73030 | <1% | 525 | $723.78 | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,516 | $699.18 |
| 12011 | <1% | 12 | $638.89 | |
| 10060 | <1% | 53 | $627.33 | |
| 76801 | <1% | 638 | $595.10 | |
| 73564 | <1% | 155 | $584.73 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,766 | $556.15 |
| 73080 | <1% | 91 | $476.32 | |
| 87400 | <1% | 6,691 | $414.57 | |
| 73610 | <1% | 1,003 | $411.89 | |
| 73140 | <1% | 69 | $297.95 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,262 | $279.60 |
| 80053 | Comprehensive metabolic panel | <1% | 17,504 | $274.26 |
| 87631 | <1% | 701 | $267.62 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,044 | $233.57 |
| 72100 | <1% | 45 | $218.13 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,455 | $121.08 |
| 29515 | <1% | 87 | $102.36 | |
| 87081 | <1% | 3,437 | $60.02 | |
| 87186 | <1% | 1,349 | $59.87 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 4,626 | $55.30 |
| 74018 | <1% | 496 | $49.62 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 515 | $37.60 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 591 | $32.39 |
| 81001 | <1% | 9,955 | $25.66 | |
| 81025 | <1% | 4,445 | $17.56 | |
| 87430 | <1% | 3,735 | $16.54 | |
| 82962 | <1% | 744 | $6.50 | |
| 81003 | <1% | 4,919 | $4.85 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,096 | $3.15 |
| 84702 | 0% | 1,016 | $0.00 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 0% | 2,477 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 2,696 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 5,171 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 60 | $0.00 |
| 85610 | 0% | 1,235 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 3,228 | $0.00 |
| 90715 | 0% | 574 | $0.00 | |
| 87420 | 0% | 1,609 | $0.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 462 | $0.00 |
| 87210 | 0% | 65 | $0.00 | |
| 86900 | 0% | 348 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 347 | $0.00 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 127 | $0.00 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 0% | 458 | $0.00 |
| 29125 | 0% | 234 | $0.00 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 3,132 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 93 | $0.00 |
| 82009 | 0% | 36 | $0.00 | |
| 73590 | 0% | 12 | $0.00 | |
| 80076 | 0% | 12 | $0.00 | |
| 82550 | 0% | 408 | $0.00 | |
| 83690 | 0% | 8,167 | $0.00 | |
| 83735 | 0% | 6,123 | $0.00 | |
| 80048 | Basic metabolic panel (calcium, ionized) | 0% | 2,846 | $0.00 |
| 85379 | 0% | 1,296 | $0.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 848 | $0.00 |
| 84703 | 0% | 5,446 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 2,193 | $0.00 |
| 86901 | 0% | 348 | $0.00 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 0% | 19,791 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 8,431 | $0.00 |
| 87088 | 0% | 3,362 | $0.00 | |
| 83880 | 0% | 610 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 1,688 | $0.00 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 0% | 13,106 | $0.00 |
| 71045 | Radiologic examination, chest; single view | 0% | 4,052 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 554 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 445 | $0.00 |
| J3490 | Unclassified drugs | 0% | 993 | $0.00 |
| 85730 | 0% | 582 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 69 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 1,207 | $0.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 4,784 | $0.00 |
| 83605 | 0% | 1,262 | $0.00 | |
| 76830 | Ultrasound, transvaginal | 0% | 306 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 143 | $0.00 |
| 84484 | 0% | 5,302 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 3,898 | $0.00 |
| 87040 | 0% | 101 | $0.00 | |
| 87077 | 0% | 616 | $0.00 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 153 | $0.00 |
| 96376 | 0% | 654 | $0.00 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 139 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 528 | $0.00 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 0% | 380 | $0.00 |
| A9150 | Non-prescription drugs | 0% | 141 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 14 | $0.00 |
| 74021 | 0% | 14 | $0.00 | |
| 87147 | 0% | 60 | $0.00 | |
| 85027 | 0% | 106 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 27 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 30 | $0.00 |
| J3590 | Unclassified biologics | 0% | 27 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 93 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 15 | $0.00 |
| 73090 | 0% | 29 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialORONA, JENNIFER (CFO)
| Provider | Location | Paid |
|---|---|---|
| Hospital Development of West Phoenix INC | Goodyear, AZ | $54.34M |
| Hospital Development of West Phoenix INC | Goodyear, AZ | $7K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.